37993-32-1

Usage

Uses

Used in Industrial Processes:
H-ACH-OME is used as a cleaning and disinfecting agent for various industrial applications, leveraging the strong acidic nature of hydrochloric acid and the bleaching properties of hydrogen peroxide. This combination effectively removes contaminants and sanitizes surfaces in manufacturing and other industrial settings.
Used in Food Production:
In the food industry, H-ACH-OME serves as a sanitizer and preservative, utilizing the mild acidity of acetic acid, commonly found in vinegar, to maintain product quality and safety. The antimicrobial properties of the solution help to extend shelf life and prevent spoilage.
Used in Household Cleaning:
H-ACH-OME is used as a multi-purpose cleaner in households, capitalizing on the cleaning power of hydrochloric acid and the disinfecting properties of hydrogen peroxide. This makes it suitable for a wide range of cleaning tasks, from kitchen surfaces to bathroom fixtures.
Used in Water Treatment:
In water treatment facilities, H-ACH-OME is employed as a disinfectant to eliminate harmful microorganisms, ensuring the safety and quality of drinking water. The oxidative power of hydrogen peroxide, along with the acidic components, contributes to the effectiveness of the treatment process.
Used in Hair and Skin Products:
H-ACH-OME finds application in hair and skin care products, where the mild acidity of acetic acid can help balance pH levels, and the bleaching properties of hydrogen peroxide can be used for color treatments and lightening hair naturally.
Used in Medical Disinfection:
In medical settings, H-ACH-OME is used as a disinfectant for surfaces and equipment, taking advantage of the antimicrobial properties of its components to minimize the risk of infection and maintain a sterile environment.

Upstream product

• 67-56-1 methanol 
• 2756-85-6 1-aminocyclohexane carboxylic acid 
• 75-36-5 acetyl chloride 
• 702-62-5 spiro(imidazolidine-4,1'-cyclohexane)-2,5-dione 
• 108-94-1 cyclohexanone 

Downstream Products

• 139456-15-8 2-Acetyl-4-p-tolyl-1,3,4-triaza-spiro[5.5]undec-2-en-5-one 
• 139456-16-9 2-Acetyl-4-(4-fluoro-phenyl)-1,3,4-triaza-spiro[5.5]undec-2-en-5-one 
• 1025935-36-7 Boc-Tyr-Ac₆c-OMe 
• 871828-14-7 methyl 1-(4-bromobenzoylamino)cyclohexanecarboxylate 
• 957122-16-6 methyl 1-{[2-[(tert-butoxycarbonyl)amino]-2-(3,5-difluorophenyl)propyl]amino}cyclohexane-1-carboxylate 
• 871828-04-5 (1-(4-ethynylbenzoylamino)cyclohexane)carboxylic acid 
• 871828-68-1 methyl 1-[4-(trimethylsilanylethynyl)benzoylamino]cyclohexanecarboxylate 
• 339153-07-0 Ac₆c-Ac₆c-OMe 
• 1025955-34-3 Phe-Ac₆c-OMe 
• 174077-36-2 Boc-Tyr-Ac₆c-OH 
• 174077-37-3 (S)-2-({1-[(S)-2-tert-Butoxycarbonylamino-3-(4-hydroxy-phenyl)-propionylamino]-cyclohexanecarbonyl}-amino)-3-phenyl-propionic acid 

Relevant academic research and scientific papers

Microwave-Assisted Ruthenium- and Rhodium-Catalyzed Couplings of α-Amino Acid Ester-Derived Phosphinamides with Alkynes

Two different types of new phosphinamide α-amino ester derivatives have been prepared in moderate to high yields via ruthenium(II) and rhodium(III)-catalyzed ortho-C?H functionalization under microwave irradiation. Specifically, the ortho-alkenylated phosphinamides were produced through coupling of phosphinamides containing an α-substituted or α,α-disubstituted α-amino ester with internal alkynes under ruthenium catalysis. In contrast, Ru and the more effective Rh-catalyzed coupling of the α-unsubstituted glycine ester phosphinamide with alkynes resulted in formation of oxidative annulation products, phosphaisoquinolin-1-ones. The developed methods feature the use of easily accessible starting materials, short reaction time, exclusive E-stereoselectivity (for ortho-alkenylation) and good functional group tolerance. The alkenylation reaction was readily scaled up to gram scale. Furthermore, the obtained alkenylated phosphinamide could be transformed into P-containing dipeptides through hydrolysis of the ester group in the catalysis product and subsequent condensation with an α-amino ester.

A COMPOUND FOR INHIBITING 11B-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same for inhibiting human 11-β-hydroxy steroid dehydrogenase type 1 (11β-HSD1). The disclosed compound and the pharmaceutical composition including the same for inhibiting human 11-β-hydroxy steroid dehydrogenase type 1 (11β-HSD1) are excellent in activity and solubility, and is more efficient in formulation and transfer.

A COMPOUND FOR INHIBITING 11BETA-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same for inhibiting human 11-beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1). The disclosed compound and the pharmaceutical composition including the same for inhibiting human 11-beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) are excellent in activity and solubility, and is more efficient in formulation and transfer.

Method for the efficient synthesis of highly-substituted oxetan- and azetidin-, dihydrofuran- and pyrrolidin-3-ones and its application to the synthesis of (±)-pseudodeflectusin

Highly substituted four- and five-membered heterocycles were prepared starting with O,P- and N,P-acetals by using a one-pot method involving base induced cyclization and a Horner-Wadsworth-Emmons (HWE) olefination reaction. Divergent synthesis of various heterocycles was achieved by using this method and transformations of the alkenyl group in the products of these processes were exemplified. Finally, a short and efficient synthesis of (±)- pseudodeflectusin based on the new methodology was achieved.

5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS

The present invention relates to 5,6-bisaryl-2-pyridinecarboxamides, to their preparation and to their therapeutic use as urotensin II receptor antagonists.

SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES

The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of substituted or unsubstituted N-cyclylalkyl-diphenylpropanamide derivatives as shown in formula (1).

MONOCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of the formula (I) : (wherein variables A1, A2, A3, A4, A5, A6, A7, A8, G1, G2, G3, G4, J, Q, Ea, Eb, Ec, R6, R7, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Substituted Sulfonamide Compounds

Substituted sulfonamide compounds corresponding to formula I pharmaceutical compositions comprising them, a process for preparing them, and the use of such compounds to treat or inhibit pain and other disorders or disease states.

Substituted monocyclic CGRP receptor antagonists

Compounds of formula I: (wherein variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.